- Home
- Companies
- north america
- hematological cancers
Refine by
Hematological Cancers Suppliers In North America
8 companies found
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a specific protein ...
based inWashington, DISTRICT OF COLUMBIA (USA)
TriStar is a Maryland LLC founded in 2003 with a business office in Washington DC. Our manufacturing, IHC and Molecular Lab is in Catania (Italy) and collaborating Medical institutes in Germany, Italy, UK & France TriStar has pioneered the use of ...
Molecular Data: No; Approx. # of Donors: 72; Follow Up Data: No; Cores per Donor: 2; Core Size: 1mm; Approx. # of Cores *: 144; TA number: TA3089; Suitable for (IHC or RNA-ISH): IHC; Suitable for CODEX/GeoMx/CosMx: ...
based inSan Diego, CALIFORNIA (USA)
Lynx Biosciences, Inc. (LynxBio) is a clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analytics with the goal of rapidly advancing drug candidates ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Hematological tumors represent the fourth most frequent cancer type in the developed world. In addition to the continuously evolving clinical guidelines2, harnessing of all the available information when ...